Affiliation:
1. Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran
2. Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Abstract
Objective:Many experiments have revealed the anti-tumor activity of spiro-quinazolinone derivatives on different cell types. Exposing KG1-a cells to N-(4- tert- butyl- 4'- oxo- 1'H- spiro [cyclohexane- 1, 2'- quinazoline]- 3'(4'H)- yl)- 4- methyl benzenesulfonamide (4t-CHQ), as an active sub-component of spiroquinazolinone benzenesulfonamides, the experiment investigated the possible mechanisms that manifest the role of 4t-CHQ in leukemic KG1-a progenitor cells. Mechanistically, the inhibitory effects of 4t-CHQ on KG1-a cells emerge from its modulating function on the expression of Bax/Bcl2 and survinin proteins.Methods:Cell viability was assessed using MTT assay. The IC50 value of cells was calculated to be 131.3μM, after 72h-incubation with 4t-CHQ, ranging from 10 to 150μM. Apoptotic changes were studied using Acridine Orange/Ethidium Bromide (AO/EB) staining. DNA fragmentation was analyzed by agarose gel electrophoresis method. To evaluate the percentage of apoptotic cells and cell growth dynamic apoptotic features, we performed Annexin V/PI double staining assay and cell cycle analysis by flow cytometry.Results:According to the results, apoptosis induction was initiated by 4t-CHQ in the KG1-a cells (at IC50 value). Cell dynamic analysis revealed that the cell cycle at the G1 phase was arrested after treatment with 4t- CHQ. Western blotting analysis showed enhancement in the expression ratio of Bax/Bcl-2, while the expression of survinin protein decreased in a time-dependent manner in the KG1-a cells. According to the docking simulation data, the effectiveness of 4t-CHQ on KG1-a cells commenced by its reactions with the functional domain of BH3 and Bcl2 and BIR domains of survivin protein.Conclusion:These results demonstrate a remarkable role of 4t- CHQ in arresting leukemia KG1-a stem cells both by induction of apoptosis as well as by down-regulating survivin and Bcl2 proteins.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Pharmacology,Molecular Medicine
Reference60 articles.
1. O’Donnell M.R.; Abboud C.N.; Altman J.; Appelbaum F.R.; Arber D.A.; Attar E.; Borate U.; Coutre S.E.; Damon L.E.; Goorha S.; Lancet J.; Maness L.J.; Marcucci G.; Millenson M.M.; Moore J.O.; Ravandi F.; Shami P.J.; Smith B.D.; Stone R.M.; Strickland S.A.; Tallman M.S.; Wang E.S.; Naganuma M.; Gregory K.M.; Acute myeloid leukemia. JNCCN 2012,10,984-1021
2. Riether C.; Schurch C.M.; Ochsenbein A.F.; Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ 2015,22,187-198
3. Guzman M.L.; Allan J.N.; Leukemia stem cells in personalized medicine. Stem Cells 2014,32,844-851
4. Sperr W.R.; Hauswirth A.W.; Florian S.; Ohler L.; Geissler K.; Valent P.; Human leukaemic stem cells: A novel target of therapy. Eur J Clin Invest 2004,34,31-40
5. Ravandi F.; Estrov Z.; Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res 2006,12,340-344
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献